Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients-Reference-Cited by-同舟云学术

Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients

Published:2004-08 Issue:4 Volume:5 Page:201-205
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Barrios Ana,Lucía Rendón Ana,Gallego Oscar,Martín-Carbonero Luz,Valer Luisa,Ríos Pilar,Maida Ivana,García-Benayas Teresa,Jiménez-Nácher Inmaculada,González-Lahoz Juan,Soriano Vincent

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1310/3HL3-HHBD-WKLR-XELL

Reference13 articles.

1. Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel

2. High-Performance Liquid Chromatographic Method for the Simultaneous Determination of the Six HIV-Protease Inhibitors and Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human Plasma

3. BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

4. In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

5. Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study;Journal of Microbiology, Immunology and Infection;2017-12

2. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi;BMC Infectious Diseases;2017-07-03

3. Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients;AIDS Research and Treatment;2015

4. Pharmacogenetics of antiretroviral therapy;Expert Opinion on Drug Metabolism & Toxicology;2014-06-18

5. Atazanavir and Other Determinants of Hyperbilirubinemia in a Cohort of 1150 HIV-Positive Patients: Results from 9 Years of Follow-Up;AIDS Patient Care and STDs;2013-07